

References

1. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. *Arthritis & Rheumatology*. 2019;71(1):5-32.
2. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. *Best Practice & Research Clinical Rheumatology*. 2021;35(2):101692.
3. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. *J Am Acad Dermatol*. 2015;73(2):242-248.
4. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. *Journal of the American Academy of Dermatology*. 2019;80(1):251-265.e219.
5. Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort. *The Journal of rheumatology*. 2016;43(1):88-96.
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine*. 2009;151(4):264-269.
7. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. *Applied health economics and health policy*. 2022;20(2):213-221.
8. Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2015;67(5):708-717.
9. Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. *Clin Rheumatol*. 2018;37(10):2751-2761.
10. Kim H, Cho SK, Kim JW, et al. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. *Seminars in Arthritis and Rheumatism*. 2020;50(3):526-533.
11. Hur P, Kim N, Dai D, Piao OW, Zheng JZ, Yi E. Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database. *Drugs - real-world outcomes*. 2021;8(1):29-38.
12. Song Y, Betts KA, Lu Y, Singh R, Clewell J, Griffith J. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis. *Rheumatol*. 2019;6(2):285-297.
13. Prince P, Skornicki M, Suruki R, Lee E, Louder A. Economic burden of joint disease in psoriasis: US claims analysis. *American Journal of Managed Care*. 2021;27(12):E406-E412.
14. Merola JF, Dennis N, Chakravarty SD, et al. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020. *Clin Rheumatol*. 2021;40(10):4061-4070.
15. Feldman SR, Pelletier CL, Wilson KL, et al. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis. *Journal of Comparative Effectiveness Research*. 2019;8(9):699-709.

16. Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. *Advances in Therapy*. 2020;37(5):2098-2115.
17. Maksabedian Hernandez EJ, Tkacz J, Lopez-Gonzalez L, Higgins K, Ogdie A, Stolshek BS. Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naive patients. *American Journal of Managed Care*. 2020;26(8):e252-e257.
18. Tsifetaki N, Migkos MP, Papagoras C, Voulgari PV, Athanasakis K, Drosos AA. Counting Costs under Severe Financial Constraints: A Cost-of-Illness Analysis of Spondyloarthropathies in a Tertiary Hospital in Greece. *Journal of Rheumatology*. 2015;42(6):963-967.
19. Kristensen LE, Jorgensen TS, Christensen R, et al. Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: A Danish cohort study. *Annals of the Rheumatic Diseases*. 2017;76(9):1495-1501.
20. Bonafede M, Tang DH, Wilson K, Huang A, Harrison DJ, Stolshek BS. Etanercept and ustekinumab dosing for plaque psoriasis and psoriatic arthritis. *American Journal of Pharmacy Benefits*. 2017;9(5):150-154.
21. Kaplan DL, Ung BL, Pelletier C, Udeze C, Khilfeh I, Tian M. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis. *Journal of Comparative Effectiveness Research*. 2021;10(12):989-998.
22. Elaine Husni M, Chang E, Broder MS, et al. Biologic Initiation Rate in Systemic-Naive Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database. *Open Access Rheumatology: Research and Reviews*. 2022;14:123-132.
23. Brodszky V, Balint P, Geher P, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. *Rheumatol Int*. 2009;30(2):199-205.
24. Esposti LD, Perrone V, Sangiorgi D, et al. Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: Findings from a real-world analysis in an Italian setting. *Patient Preference and Adherence*. 2019;13:187-194.
25. Mars NJ, Kerola AM, Kauppi MJ, Pirinen M, Elonheimo O, Sokka-Isler T. Patients with rheumatic diseases share similar patterns of healthcare resource utilization. *Scand J Rheumatol*. 2019;48(4):300-307.
26. Martinez-Lopez-de-Castro N, Alvarez-Payero M, Samartin-Ucha M, et al. Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study. *Clinical and experimental rheumatology*. 2020;03.
27. Perrone V, Giacomini E, Sangiorgi D, et al. Treatment pattern analysis and health-care resource consumption on patients with psoriatic arthritis or ankylosing spondylitis treated with biological drugs in a northern Italian region. *Therapeutics and Clinical Risk Management*. 2020;16:509-521.
28. Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. *Annals of the Rheumatic Diseases*. 2006;65(9):1175-1183.
29. Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: Data from real-life follow-up of patients in the NOR-DMARD registry. *Rheumatology (United Kingdom)*. 2012;51(9):1618-1627.
30. Kawalec P, Malinowski KP, Pilc A. Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. *Rheumatol Int*. 2016;36(9):1223-1230.

31. Olivieri I, Cortesi PA, De Portu S, et al. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. *Clinical and Experimental Rheumatology*. 2016;34(1):68-75.
32. Zhu TY, Tam LS, Leung YY, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: Direct and indirect costs and the influence of disease pattern. *Journal of Rheumatology*. 2010;37(6):1214-1220.
33. Orbai AM, Reddy S, Peterson S, et al. Work absenteeism and disability associated with psoriatic arthritis and psoriasis in the United States study of claims data from 2009 to 2020. *Journal of Clinical Rheumatology*. 2021;27(SUPPL 1):S138-S139.
34. Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Health resource utilization and associated healthcare costs of biologic disease-modifying antirheumatic drugs in German patients with psoriatic arthritis. *Arthritis care & research*. 2021;20.
35. Orbai AM, Reddy S, Villacorta R, et al. Pmu31 Absenteeism and Work Disability Associated with Psoriasis and Psoriatic Arthritis in the US. *Value in Health*. 2020;23(Supplement 1):S238-S239.
36. Husni E, Peterson S, Dennis N, et al. Work disability associated with fatigue in patients with psoriatic arthritis a retrospective study using claims data, 2009-2019. *Arthritis and Rheumatology*. 2021;73(SUPPL 9):478-480.
37. Guraya A, Sanwo EJ, Nair KM, Kannayiram SS, Idolor ON, Odion JO. Psoriatic Arthritis Hospitalization Is Associated with Increased Health Care Charges: A Report from the National Inpatient Sample. *Cureus*. 2020;12(12):e12275.
38. Murugesan V, Piliitsi ME, Rabasa G, Dubreuil M. National trends in hospitalizations for serious infections in patients with psoriatic arthritis using the national inpatient sample 2012-2017. *Journal of Psoriasis and Psoriatic Arthritis*. 2021;6(4):217-218.
39. Inui K, Sato M, Esterberg E, Parikh RC, Kimura S, Torisu-Itakura H. Treatment practices and costs among patients with psoriatic arthritis: A Japanese hospital claims database analysis. *Mod Rheumatol*. 2021;31(6):1179-1191.